Anti-WT1-associated protein / WTAP, clone PCRP-WTAP-1A4

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide. Wilms tumor (WT) is an embryonal malignancy of the kidney that affects 1 in 10,000 infants and is observed in both sporadic and inherited forms. The Wilms tumor protein (WT1) binds the DNA sequence GCGGGGGCG, a recognition element common to the early growth response (Egr) family of Zn2+ finger transcriptional activators, and functions as a transcriptional repressor. WTAP (wilms tumor 1-associating protein) is a ubiquitously expressed nuclear protein that interacts with WT1 and may be involved in regulating mRNA splicing. WTAP is found in nuclear speckles, where it regulates the G2/M cell cycle transition by binding to the 3' UTR of cyclin A2, thus enhancing its stability. Additionally, WTAP inhibits expression of WT1 target genes and is able to impair the ability of WT1 to bind DNA. Two isoforms of WTAP exist due to alternative splicing events. Protein function: Associated component of the WMM complex, a complex that mediates N6-methyladenosine (m6A) methylation of RNAs, a modification that plays a role in the efficiency of mRNA splicing and RNA processing (PubMed:29507755). Required for accumulation of METTL3 and METTL14 to nuclear speckle (PubMed:24316715, PubMed:24407421, PubMed:24981863). Acts as a mRNA splicing regulator (PubMed:12444081). Regulates G2/M cell-cycle transition by binding to the 3' UTR of CCNA2, which enhances its stability (PubMed:17088532). Impairs WT1 DNA-binding ability and inhibits expression of WT1 target genes (PubMed:17095724). [The UniProt Consortium]